Trial in Progress: Phase 1 Trial of Arlocabtagene Autoleucel (Arlo-Cel) Plus Mezigdomide (MEZI) or Elranatamab (ELRA) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-510; Pres time: Sep 23, 2026; P1 | "This trial will evaluate arlo-cel combinations, including with MEZI and ELRA maintenance, in RRMM."
Clinical • P1 data • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • IKZF1
|
|
Susan Bal1; Luciano J. Costa1; Nizar J. Bahlis2; Omar Nadeem3; Christine Chen4; Jingmei Hsu5; Myo Htut6; Krina Patel7; David S. Siegel8; Julia Erin Wiedmeier-Nutor9; Christopher R. D’Angelo10; Ehsan Malek11; Scott R. Solomon12; Timothy B. Campbell13; Jaclyn Davis13; Ziyan Guo13; Jennifer Han13; Hongxiang Hu13; Krishna R. Juluri13; Jessica Katz13; Liane Kuo13; Sifiyya Ziyad13; Sham Mailankody14
|